1217643-68-9

1217643-68-9 structure

Name: Clopidogrel-d3 hydrogen sulfate
Chemical Name: Clopidogrel-d3 hydrogen sulfate
CAS Number: 1217643-68-9
Molecular Formula: C₁₆H₁₅D₃ClNO₆S₂
Molecular Weight: 422.92
Catalog: Signaling Pathways GPCR/G Protein P2Y Receptor
Create Date: 2023-04-20 23:51:33
Modify Date: 2024-01-03 17:19:50
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Name	Clopidogrel-d3 hydrogen sulfate

Description	Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Cytochrome P450 Signaling Pathways >> GPCR/G Protein >> P2Y Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Katsunobu Hagihara, et al. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, Clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412-20. [3]. Jean-Marc Herbert, et al. P2Y12, a new platelet ADP receptor, target of Clopidogrel.Semin Vasc Med. 2003 May;3(2):113-22. [4]. Hai-Lu Wu, et al. Increased endoplasmic reticulum stress response is involved in Clopidogrel-induced apoptosis of gastric epithelial cells. PLoS One. 2013 Sep 13;8(9):e74381. [5]. Ran Ni, et al. Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model.Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2338-2344. [6]. Kuszynski DS, et al. Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery [published online ahead of print, 2021 Oct 1]. Eur J Pharmacol. 2021;174545.

Molecular Formula	C₁₆H₁₅D₃ClNO₆S₂
Molecular Weight	422.92

1217643-68-9	1246814-55-0
2468372-74-7	120202-66-6
2140305-74-2	6209-50-3
58745-44-1	32503-27-8
3803-84-7	53486-30-9
1289067-46-4	1158522-08-7
940364-43-2	134104-43-1
1909314-03-9	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4